Stimulant medications for the treatment of ADHD: Efficacy and limitations

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 5, Issue 3, 1999, Pages 215-224

  Wigal, Tim ^a,b   Swanson, James M ^b   Regino, Roland ^b   Lerner, Marc A ^b   Soliman, Ihab ^b   Steinhoff, Ken ^b   Gurbani, Suresh ^b   Wigal, Sharon B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Attention deficit disorder; Children; CNS stimulating drugs; Drug therapy; Literature review; Meta analysis

Indexed keywords

AMPHETAMINE; METHYLPHENIDATE; PEMOLINE MAGNESIUM; PSYCHOSTIMULANT AGENT;

ACADEMIC ACHIEVEMENT; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COGNITION; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; GENETICS; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; REVIEW;

EID: 0032856287     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2779(1999)5:3<215::AID-MRDD8>3.0.CO;2-K     Document Type: Review

References (107)

1. Abbott Drug Monograph. 1975. Cylert (Pemoline). Chicago. IL: Abbott Laboratories.
2. Abbott Letter. 1996. (December). Drug warning concerning Cylert (pemoline). Chicago, IL: Abbott Laboratories.
3. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders: fourth edition. Washington, DC: Author.
4. Arnold LE, Abikorff HB. Cantwell DP, et al. 1997. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. J Attn Disord 2:141-158.
5. Barkley RA, Cunningham CE. 1978. Do stimulant drugs improve the academic performance of hyperkinetic children? A review of outcome studies. Clin Pediatr 17:85-92.
6. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. 1990. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 86:184-192.
7. Barkley RA. 1997. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychological Bulletin 121:65-94.
8. Breggin P. 1998. Does clozapine treatment cause brain disease? Arch Gen Psychiatry 55:845.
9. Buitelaar JK. Van der Gaag RJ, Swaab-Barneveld H, et al. 1995. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:1025-1032.
10. Cantwell DP, Swanson JM, Connor DF. 1997. Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiatry 36:539-544.
11. Carlson CL, Bunner MR. 1993. Effects of methylphenidate on the academic performance of children with attention-deficit hyperactivity disorder and learning disabilities. School Psychol Rev 22:184-198.
12. Carlson CL, Pelham WE, Milich R, et al. 1992. Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder. J Abnorm Child Psychol 20:213-232.
13. Castellanos FX, Elia J, Kruesi MJP, et al. 1994. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res 52:305-316.
14. Castellanos FX. 1997. Toward a pathophysiology of attention-deficit/hyperactivity disorder. Clinical Pediatrics 36:381-393.
15. Chan Y, Swanson J, Soldin S, et al. 1983. Methylphenidate hydrochloride given with or before breakfast: II. Effects of plasma concentration of methylphenidate and ritalinic acid. Pediatrics 72:56-59.
16. Cole J. 1969. The amphetamines in child psychiatry: a review. Semin Psychiatry 1:174-178.
17. Congress of the United States, House of Representatives. 1996. (July 16). Hearing to examine the approaches of the DOE and NIMH regarding the diagnosis and treatment of ADHD.
18. Cook EH, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Keiffer JE, et al. 1995. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993-998.
19. Cooper HM. 1988. Organizing knowledge synthesis: a taxonomy of literature reviews. Knowl Soc 1:104-126.
20. Cooper HM. 1989. Integrating research: a guide for literature reviews. 2nd edition. Newbury Park: Sage Publications.
21. Diller L. 1996. The run on Ritalin. Hastings Center Rep 26:12-18.
22. Douglas VB, Desilets J, Sherman E. 1995. Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 34:877-885.
23. Dunnick JK, Hailey JR. 1995. Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology 103:77-84.
24. Elia J, Borcherding B, Rapoport J. 1991. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatiy Res 36:141-155.
25. Ellinwood EH, King G, Lee TH, Joyner CM, Zhang H. 1992. Behavioral neurobiological effects of chronic cocaine administration: contrasts between administration paradigms as well as times after withdrawal. Clinical Neuropharmacology 15:646-647.
26. Fenischel R. 1995. Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolesc Psychopharmacol 5:155-156.
27. Feussner G. 1998. Diversion, trafficking, and abuse of methylphenidate. Abstract in: Diagnosis and treatment of attention deficit hyperactivity disorder. NIH Concensus Conference. Bethesda, Maryland.
28. Filipek PA, Semrud-Clikeman M, Steingard RJ, et al. 1997. Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology 48:589-601.
29. Food and Drug Administration. 1995. Toxicology and carcinogenesis studies of methylphenidate hydrochloride in F344/n rats and B6C3F mice. NIH publication no. 95-3355. U.S. Department of Health and Human Services.
30. Forness SR, Cantwell DP, Swanson JM, et al. 1991. Differential effects of stimulant medication on reading performance of boys with hyperactivity with and without conduct disorder, J Learn Disabil 24:304-310.
31. Gadow KD, Sverd J, Sprafkin J, et al. 1996. Efficacy of methylphenidate for ADD children with tic disorder. Ann Prog Child Psychiatry Child Dev 494-522.
32. Gainetdinov RR, Westel WC, Jpnes SR, et al. 1999. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283:397-401.
33. Gibbs N. 1998. (Nov. 30). The age of Ritalin. Time 87-96.
34. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. 1997. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 2:311-313.
35. Gillberg C, Melander H, Von Knorring AL, et al. 1997. Long-term stimulant treatment of children with attention deficit hyperactivity disorder symptoms. Arch Gen Psychiatry 54:857-864.
36. Gladwell M. 1999. (Feb. 15). Running from Ritalin. New Yorker 80-84.
37. Greenhill L, Abikoff H, Arnold L, et al. 1996. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 35:1304-1313.
38. Greenhill L. 1998. Multimodal treatment study of children with ADHD: 14-month outcomes IV. Presented at the 45th annual meeting of the American Academy of Child and Adolescent Psychiatry in Anaheim, CA.
39. Hallowell EM, Ratty JJ. 1995. Driven to distraction. New York: Touchstone Press.
40. Haislip G. 1996. Stimulant use in the treatment of ADHD. San Antonio Conference Report sponsored by the US Department of Justice & the DEA. p 1-6.
41. Hinshaw S. 1998. Multimodal treatment study of children with ADHD: 14-month outcomes II. Presented at the 45th annual meeting of the American Academy of Child and Adolescent Psychiatry in Anaheim, CA.
42. Hinshaw S. 1999. Effects of comorbidity anxiety disorder, family poverty, session attendance, and community medication on treatment outcome for attention-deficit hyperactivity disorder. Arch Gen Psychiatry (in press).
43. Hinshaw S. 1999. MTA Cooperative Group - Moderators and mediators of treatment response for children with ADHD: the MTA study submitted to Archives of General Psychiatry (in press).
44. Hinshaw S. 1991. Stimulant medication and the treatment of aggression in children with attentional deficits. J Clin Child Psychiatry 20:301-312.
45. Hinshaw S, Melnick SM. 1995. Peer relationships in boys with attention-deficit hyperactivity disorder with and without comorbid aggression. Special Issue: Developmental processes in peer relations and psychopathology. Dev Psychopathol 7:627-647.
46. Hoza B, Pelham WE, Sams SE, et al. 1992. An examination of the dosage effects of both behavior therapy and methylphenidate on the classroom performance of two ADHD children. Special Issue: Treatment of children with attention-deficit hyperactivity disorder (ADHD). Behav Modif 16:164-192.
47. The 1CD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines, tenth revision. Geneva: World Health Organization; 1993.
48. Jacobson NS, Truax P. 1991. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59:12-19.
49. Jensen P, Payne J. 1998. Behavioral and medication treatments for attention deficit hyperactivity disorder: comparisons and combinations [Abstract]. In: Diagnosis and treatment of attention deficit hyperactivity disorder. Paper presented at the National Institute of Health Consensus Development Conference.
50. Jensen P for the MTA Group. 1999. 14-Month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder (in press). Arch Genn Psychiatry
51. Klein RG, Abikoff H. 1997. Behavior therapy and methylphenidate in the treatment of children with ADHD. J Attn Disord 2:89-114.
52. Kohn A. 1989. Suffer the restless children. Atlantic Monthly 99-98.
53. LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N, et al. 1996. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1:121-124.
54. Lambert NM. Adolescent outcomes for hyperactive children. 1988. Perspectives on general and specific patterns of childhood risk for adolescent educational, social, and mental health problems. Am Psychol 43:786-799.
55. Marx J. 1999. How stimulant drugs may calm hyperactivity. Science 283-306.
56. McGuiness D. 1989. Attention deficit disorder: the emperor's clothes, animal "pharm," and other fictions. Hillsdale. NJ: Lawrence Erlbaum.
57. Milich R, Loncy J. 1979. The role of hyperactive and aggressive symptomatology in predicting adolescent outcome among hyperactive children. J Pediatr Psychol 4:93-112.
58. Milichap JG, Boldery EE. 1967. Studies in hyperkinetic behavior, II: laboratory and clinical evaluations of drug treatments. Neurology 17:467-471.
59. Moscaritola JD. 1996. Dear Doctor Letter to CibaGeneva Pharmaceuticals.
60. Nehra A, Mullick F, Ishak KG, et al. 1990. Pemoline-associated hepatic injury. Gastroenterology 98:1517-1518.
61. Pelham WE, Carlson CC, Sams SE, Vallano G, Dixon MJ, Hoza B. 1993. Separate and combined effects of methylphenidate and behavior modification on boys with ADHD in the classroom. J Consulting and Clin Psychology 61:505-515.
62. Pelham WE, Swanson JM, Bender Furman M, et al. 1995. Pemoline effects on children with ADHD: a time response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 34:1504-1513.
63. Pliszka SR, Greenhill LL. Crimson ML, and the Texas Consensus Panel on Medication Treatment of Childhood ADHD. 1999. The Texas Childhood Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention Deficit Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry (in press).
64. Rapoport J, Buchsbaum M, Zahn T, et al. 1978. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 199:560-563.
65. Rapport MD, Denney C, DuPaul GJ, et al. 1994. Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry 33:882-893.
66. Richters J, Arnold L, Jensen P, et al. 1995. The National Institute of Mental Health Collaborative Multisite, Multimodal Treatment Study of Children with Attention-deficit Hyperactivity Disorder (MTA): I. Background and rationale. J Am Acad Child Adolesc Psychiatry 34:987-1000.
67. Riddle MA, Lynch KA, Scahill L, et al. 1995. Methylphenidate discontinuation and reinitiation during long-term treatment of children with Tourette's disorder and attention-deficit hyperactivity disorder: a pilot study. J Child Adolesc Psychopharmacol 5:205-214.
68. Robbins TW, Sahakian BJ. 1979. "Paradoxical" effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioural pharmacology. Neuropharmacology 18:931-950.
69. Robinson TE, Jurson PA, Bennett JA, et al. 1988. Persistent sensitization of dopamine neurotransmission in ventral striatum (nudes accumbens) produced by prior experience with (+) amphetamine: a microdialysis study in freely moving rats. Brain Res 462:211-222.
70. Robinson TE, Jurson PA, Bennett JA. Bentgen KM. 1988. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res 462:211-222.
71. Safer DJ, Zito JM, Fine EM. 1996. Increased methylphenidate usage for ADD in the 1990s. Pediatrics 98:1084-1088.
72. Sahakian BJ, Robbins TW. 1977. Are the effects of psychomotor stimulant drugs on hyperactive children really paradoxical? Medical Hypotheses 3:154-158.
73. Sallee FR, Stiller RL, Perel JM. 1992. Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 31:244-251.
74. Schachar R, Tannock R. 1993. Childhood hyperactivity and psychostimulants: a review of extended treatment studies. J Child Adolesc Psychophannacol 3:81-97.
75. Schachar R, Tannock R, Cunningham C, et al. 1997. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 36:754-763.
76. Schenk S. 1996. Is treatment with psychostimulants a risk factor for substance abuse? San Antonio Conference report sponsored by the US Department of Justice and the DEA. p 27-29.
77. Schrag P, Divorky D. 1975. The myth of the hyperactive child and other means of child control. New York: Pantheon Books.
78. Shaywitz S, Shaywitz B. 1987. Attention deficit disorder: current perspectives. Pediatr Neurol 3:129-135.
79. Shaywitz S, Shaywitz B. 1991. Attention deficit disorder: diagnosis and role of Ritalin in management. New York: Mary Ann Liebert.
80. Smalley SL, Bailey JN, Palmer CG, Cantwell DP, McGough JJ, Del'Homme MA, Asamow JR, Woodward JA, Ramsey C, Nelson SF. 1998. Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder. Molecular Psychiatry 3:427-430.
81. Solanto M. 1998. Neuropsychopharmacological mechanisms of stimulant drug action in attention deficit/hyperactivity disorder: a review and integration. Behavior Brain Res.
82. Sprague R, Sleator E. 1976. Drugs and dosages: implications for learning disabilities. Baltimore: University Park Press.
83. Stein MA, Blondis TA, Schnitzler ER, et al. 1996. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 98:748-756.
84. Stevenson RD, Wolraich ML. 1989. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatr Clin North Am 36:1183-1197
85. Swanson JM, Flockhart D, Udrea D, et al. 1995. Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolesc Psychopharmacol 5:301-304.
86. Swanson JM, Kinsbourne M. 1976. Stimulant-related state-dependent learning in hyperactive children. Science 192:1354-1357.
87. Swanson JM, McBurnett K, Wigal T, et al. 1993. Effect of stimulant medication on children with attention deficit disorder: a "review of reviews." Except Childr 60:154-162.
88. Swanson JM, Wigal S, Greenhill L, et al. 1998a. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 37:519-526.
89. Swanson JM, Wigal S, Greenhill L, et al. 1998b. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 34:55-60.
90. Swanson JM. 1998. Multimodal treatment study of children with ADHD: 14-month outcomes III. Presented at the 45th annual meeting of the American Academy of Child and Adolescent Psychiatry in Anaheim, CA.
91. Swanson JM, Connor D, Cantwell D. 1999. The combination of methylphenidate and clonidine is ill-advised. J Am Acad Child Adolesc Psychiatry (in press).
92. Swanson JM, Castellanos FX. 1998. Biological bases of ADHD: Neuroanatomy, genetics, and pathophysiology. Abstract in: Diagnosis and treatment of attention deficit hyperactivity disorder. NIH Concensus Conference. Bethesda, Maryland.
93. Swanson JM, Sunohara GA, Kennedy JL, Regino R, Fineberg E. Wigal T, Lerner M, Williams L, LaHoste GJ, Wigal S. 1998. Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family-based approach. Mol Psychiatry 3:38-41.
94. Swanson JM, Conner DF, Cantwell D. 1999. III-Advised. Debate Forum. J Am Acad Child Adolesc Psychiatry 38:5.
95. Tannock R, Schachar R, Logan G. 1995. Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. J Abnorm Child Psychol 23:235-266.
96. Taylor E, Schachar R, Thorley G, et al. 1987. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 17:121-143.
97. US Department of Education. 1994. Report on four ADD centers. Washington, DC: Author.
98. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, Gabneli JD. 1998. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study, Proceedings of the National Academy of Sciences of the United States of America. 95:14494-14499.
99. Voeller K. 1991. Toward a neurobiologie nosology of attention deficit hyperactivity disorder. J Child Neurol 6:2-8.
100. Volkow ND, Wang GJ, Fowler JS. et al. 1998. Differences in regional brain metabolic responses between single and repeated doses of methylphenidate. Psychiatry Res 83:29-36.
101. Volkow ND, Wang GJ, Fowler JS, et al. 1997. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am J Psychiatry 154:50-55.
102. Wallis C. 1994. (July 18). Life in overdrive. Time 43-50.
103. Wilens TE, Biederman J. 1992. The stimulants. Psychiatr Clin North Am 15:191-222.
104. Wilens TE, Spencer TJ. 1999. The combination of methylphenidate and clonidine is recommended. J Am Acad Child Adolesc Psychiatry (in press).
105. Wilens TE, Spencer TJ, Swanson JM. Connor DF, Cantwell D. 1999. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 38:614-619.
106. Wilens TE, Spencer TJ, Biederman J. 1997. Sudden (un)explamed death [Letter]. J Am Acad Child Adolesc Psychiatry 36:1487-1488.
107. Wolraich ML. 1998. Current assessment and treatment practices. Abstract in: Diagnosis and treatment of attention deficit hyperactivity disorder. NIH Consensus Conference. Bethesda, Maryland.